English Deutsch 中文
XinTech
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
XinTech
Menu Deutsch 中文

BioQuiddity and Lee’s Pharmaceutical to Jointly Commercialize Two Infusion Drugs

Aug. 24, 2015

On August 24, 2015 BioQuiddity Incorporated and Lee’s Pharmaceutical (HK) Limited announced the signing of a strategic license and supply agreement for the registration and commercialization of BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products in the PRC, Taiwan, Hong Kong, and Macau.

BioQuiddity’s unit-dose infusible pharmaceuticals are comprised of the pharmaceutical, delivery system and administration line in a self-contained, single use, ready-to-use presentation. The ropivacaine pharmaceutical is prefilled with 0.2% ropivacaine and is intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQuiddity’s propofol infusion pharmaceutical features both programmable flow and bolus capabilities.